NICE has today also published a new discussion aid to support shared decision making about HRT, focusing on the key risks and benefits to consider. The guideline clarifies that whilst HRT has some ...

Suggested remit: To appraise the clinical and cost effectiveness of talquetamab within its marketing authorisation for treating relapsed or refractory multiple myeloma after 3 treatments.

Avapritinib (Ayvakyt) is indicated 'as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM ...

Avapritinib is recommended, within its marketing authorisation, as an option for treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an ...

There is a simple discount patient access scheme for avapritinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non‑NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

The evaluation committee considered evidence submitted by Blueprint Medicines, a review of this submission by the external assessment group (EAG) and responses from stakeholders. See the committee ...

Review and download supporting evidence. Includes the full guideline if available.

A list of downloadable documents created during development.